MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
The Pharma Data
JANUARY 13, 2021
Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs.
Let's personalize your content